Shopping Cart
- Remove All
- Your shopping cart is currently empty
Efaproxiral (RSR13) is a hemoglobin allosteric modifier, a potential radiosensitizer and chemotherapy enhancer in cancer treatment, improving tumor oxygenation.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
10 mg | $30 | In Stock | |
25 mg | $46 | In Stock | |
50 mg | $71 | In Stock | |
100 mg | $98 | In Stock | |
200 mg | $152 | In Stock | |
1 mL x 10 mM (in DMSO) | $74 | In Stock |
Description | Efaproxiral (RSR13) is a hemoglobin allosteric modifier, a potential radiosensitizer and chemotherapy enhancer in cancer treatment, improving tumor oxygenation. |
Targets&IC50 | INS1 (832/13) cells:6 nM (EC50) |
In vivo | Treatment with Efaproxiral(150 mg/kg, ip) significantly increased oxygenation in RIF-1 tumors implanted in C3H mice and increased the ability of radiotherapy to inhibit tumor growth within 5 days. [1] Efaproxiral may increase the oxygenation capacity of intracranial tumors. [2] |
Alias | RSR-13, RSR13, GSJ61, GSJ 61, Efaproxyn |
Molecular Weight | 341.4 |
Formula | C20H23NO4 |
Cas No. | 131179-95-8 |
Smiles | O=C(O)C(OC1=CC=C(C=C1)CC(=O)NC=2C=C(C=C(C2)C)C)(C)C |
Relative Density. | 1.202 g/cm3 (Predicted) |
Storage | keep away from moisture,store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
Solubility Information | H2O: < 1 mg/mL (insoluble) DMSO: 120 mg/mL (351.49 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.